Aura Biosciences (AURA) said Monday that data from a completed phase 1 trial of bel-sar in patients with non-muscle-invasive bladder cancer demonstrated a "robust anti-tumor immune response."
The company said the trial enrolled 15 patients, with primary endpoints of evaluating the safety and feasibility of bel-sar alone in five patients and bel-sar with light activation in 10 patients.
Clinical complete responses were observed with a single, low dose of bel-sar in patients with intermediate and high-risk non-muscle-invasive bladder cancer, supporting bel-sar's potential as a new treatment instead of, or ahead of, the standard of care procedure, the company said.
Bel-sar was also well tolerated as drug-related grade 1 events were reported in less than 10% of the patients, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.